I Horge’s research while affiliated with Spitalul Clinic de Urgență pentru Copii Cluj-Napoca and other places

The purpose of this paper is to evidence the advantages of artificial Acrysof Toric IOL implantation in patients with cataract and corneal astigmatism. Prospective clinical study on 30 patients with cataract operated on with phacoemulsification and implantation of Acrysof Toric IOL on 32 eyes, between September 2007- March 2008. The predictability between estimated and obtained astigmatism is 96.87%. In most of the cases the IOL was well centered in the capsular bag and stable on the predetermined axis, in 1 eye the IOL was rotated with about 30 degrees. The astigmatism evaluated in all patients at 6 months postoperatively being corrected in 78.13% of cases and reduced in 21.87% of cases. The UCVA between 2/3-5/5 was in 65.63% of cases and BCVA was in 34.37% of cases. To mention that 63.63% of patients with BCVA wanted to remain with myopia. Phacoemulsification and Acrysof Toric IOL implantation are an attractive alternative for patients with cataract and corneal astigmatism. The Acrysof Toric IOL eliminates or reduces preoperatively astigmatism, providing many patients a clear distance vision without glasses.

Age Related Macular Degeneration (ARMD) is a complex and multifactorial disease, without an etiology and an etiological treatment discovered so far. The current work is trying to present the actual knowledge regarding the most important risk factors related to the pathology of ARMD.

The aim of laser photocoagulation in diabetic retinopathy is to stop the development of retinal neovessels and even to determine their involution. Early applied, laser photocoagulation can significantly reduce the risk of severe visual loss. The knowledge of the multiple mechanisms of laser photocoagulation leads to the possibility to introduce a well dosed treatment that is appropriate for the clinical stage of the retinopathy.

We present the case of a 70 years old female patient with bilateral senile cataract, more advanced at the RE; Primary open angle glaucoma, poor compensation with drugs at the RE (with timolol 0.5% and xalatan 0.005%). Combined cataract and glaucoma surgery was performed, using different surgical approach zones. The article describes the therapeutic options in the morbid association of cataract and glaucoma, pointing out the advantages and the indications for each method.

The purpose of this paper is to appreciate the Acrysof Natural IOL comportment during the implantation after phacoemulsification, and to evaluate the visual acuity at 2 months and 2 years postoperative. Prospective clinical study which comprises 48 patients( 48 eyes) with cataract operated on with phacoemulsification and implantation of Acrysof Natural IOL with the Monarch II injector and the implantation forceps. The patients' age was between 4- 82 years; The IOLs were introduced with the Monarch II injector in 47 cases and with the implantation forceps in 1 case; No IOL was damaged during the implantation; The unfolding and the rotation of the IOL were possible in all cases, without incidents; The visual acuity appreciated 2 months and 2 years postoperative was good in the most of the cases; the chromophore pigment did not influence the quality of vision and the color perception. The implantation of the Acrysof Natural IOL is identical with the implantation of the Acrysof single piece IOL, is easy to perform and completely atraumatic.

The comparative analyses of the standard Legacy 20000 efficiency and the AdvanTec Legacy efficiency take into consideration the effective phacoemulsification time, power, and the postoperative clinical outcomes. Retrospective clinical study which comprises 2 groups of patients operated on with phacoemulsification: 200 eyes were operated on using the classic handpiece of the Legacy 20000 system; 200 eyes were operated on using the AdvanTec Legacy system and the NeoSoniX handpiece. The effective phacoemulsification time in the standard Legacy group was under 0.4 min in 40 cases (20%), between 0.4-1.2 min in 120 cases (60%), and more than 1.2 min in 40 cases (20%). The effective phaco time in the AdvanTec-NeoSoniX group was under 0.4 min in 118 cases (59%), between 0.4-1.2 min in 72 cases (36%) and more than 1.2 min in 10 cases (5%). The mean phacoemulsification power varied between 19-38% in the first group and 14-22% in the second group. Descemetic striae and corneal edema on the first postoperative day were observed in 38 eyes (19%) in the Legacy standard group, and 18 eyes (9%) in the AvanTec-NeoSonix group. The progression from the standard Legacy to the AdvanTec Legacy system with NeoSoniX handpiece led to the reduction in phacoemulsification power by two mechanisms, oscillation, which breaks the nucleus, and vacuum, which removes and evacuates the nuclear material.

We try to clarify some controversies related to the palpebral epitheliomas, controversies related to the therapeutical applied attitude (surgery, radiotherapy or the association of the two therapeutical methods), to the indications and contraindications of their application. It is a review study of the Military Hospital and Oncologic Institute Cluj-Napoca casuistry between 1984-1994, which comprises 244 patients with palpebral epitheliomas, histologically confirmed. This casuistry was followed taking into consideration the age, sex, histological type, anatomo clinical presentation, TNM clinical stage, the localisation of the tumor, the type of the applied treatment, complications, healing and the therapeutical failures. The efficiency of the applied therapeutical methods was considered related to their obtained results to the therapeutical failures. The rate of healing at 5 years was 90.57% for the whole group. 1. The two methods of treatment seems to be equally sensible concerning the therapeutical efficiency in stages I and II. 2. In the advanced stages (III and IV) our option is for mixing the two methods. An optimum treatment for each patient is possible only if there is a close cooperation between the ophthalmologist-surgeon, plastic surgeon and the radiation oncologist.